How We Got Here: AbbVie in Oncology

Our oncology story began with a focus on attacking an “unhittable” cancer target.

abbvie_in_oncology_hero.jpg

From creating the first BCL-2 inhibitor to come to market, to pursuing a pipeline focused on the toughest cancers to treat, AbbVie’s oncology scientists understand that outsmarting cancer takes a potent combination of courage, scientific prowess and strategy.

“When you’re trying to find new treatments for patients facing unrelenting cancers, there’s an obvious urgency to the work,” says Rod A. Humerickhouse, M.D., Ph.D., group project leader, oncology development, AbbVie. “But you need to balance the impatience you feel, wanting answers now, with the reality of drug discovery in this area… disappointment is part of the job description, but you have to funnel that frustration, learn from your experiences and use that to propel you forward.”

In advance of this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, we took the time to look back at where we started, and examine how that pioneering spirit informs how we’re moving ahead. We also asked some of our oncology leaders to share how we’re joining with our community and our industry to prepare for what’s to come in the battle against cancer.
 

Breaking the Rules and Paving the Way

Breaking the Rules of Science to Treat Cancer

Back in the 1990s, a group of AbbVie scientists were fixated on understanding the way cells die – and why cancer cells were so resistant to whatever this process was. Finding answers to these questions not only resulted in a new treatment option and a future of possibilities in treating several forms of blood cancer, but also paved the way for researchers around the world to create innovative medicines.

BTK Protein: The Good, the Bad & The Ugly

Bruton’s tyrosine kinase (BTK) might well be considered the Jeckyl and Hyde of the body. When working correctly, it helps immune function; when it goes awry, it can lead to the proliferation of B cells instrumental to the development of leukemia or lymphoma. Could inhibiting the ugly side of BTK result in new treatments for certain B cell cancers? AbbVie researchers explain why they’re determined to find out.
 

Hope for Tomorrow

Three Reasons I’m Excited about the Future of Cancer Treatment

Many of the treatments available to cancer patients today were just pipe dreams when Danelle James, M.D., M.A.S. started her career in oncology. As we enter the era of personalized medicine, James explains why drug discovery isn’t simply about attacking cancer anymore: now, it’s also about protecting a patient’s quality of life.

Rethinking Cure in Cancer Treatment

Could reframing cancer as a chronic condition change the way we approach treatment? An oncology medical director imagines a paradigm shift that could face the challenge of recurrence head on – and explains how we’re getting closer to making this a reality.
 

Conquering Cancer’s Complexity

Five Reasons Small Cell Lung Cancer is Tough to Treat

When you’re trying to beat a disease that keeps fighting back, it’s important to have many tools in your arsenal. For SCLC patients, there are far too few options for a cancer that won’t give up. But scientists won’t give up, either. Learn about some of the ideas AbbVie is researching to help level the playing field.

What Makes AML Different?

When asked about acute myeloid leukemia (AML), doctors, researchers and patient advocates almost always answer with the same word: devastating. As we look to advance options for those with this pervasively aggressive disease, an AbbVie researcher explains why for older patients in particular, AML is a complex cancer to treat.

Media inquiries

 

Sign Up

Jack Hirschfield
Email: jack.hirschfield@abbvie.com
Call: +1 224-458-0943
  Stay up to date on recent news, stories and more by signing up for our topic alerts.
Share this Story: Share to Facebook Share to Twitter Share to Linkedin Email